$275 Million is the total value of Affinity Asset Advisors, LLC's 55 reported holdings in Q4 2021. The portfolio turnover from Q3 2021 to Q4 2021 was 68.5% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| MORF | Buy | MORPHIC HLDG INC | $18,919,000 | +23.4% | 399,302 | +47.5% | 6.87% | +77.4% |
| SWTX | Buy | SPRINGWORKS THERAPEUTICS INC | $18,504,000 | +131.5% | 298,545 | +136.9% | 6.72% | +232.8% |
| SAVA | Buy | CASSAVA SCIENCES INCput | $15,295,000 | +228.5% | 350,000 | +366.7% | 5.55% | +372.3% |
| VINC | Buy | VINCERX PHARMA INC | $11,569,000 | -28.8% | 1,135,365 | +13.0% | 4.20% | +2.4% |
| NARI | Sell | INARI MED INC | $11,409,000 | +4.2% | 125,000 | -7.4% | 4.14% | +49.8% |
| ZNTL | Buy | ZENTALIS PHARMACEUTICALS INC | $9,877,000 | +91.2% | 117,500 | +51.6% | 3.59% | +175.1% |
| ARNA | New | ARENA PHARMACEUTICALS INC | $9,294,000 | – | 100,000 | +100.0% | 3.38% | – |
| KDNY | Buy | CHINOOK THERAPEUTICS INC | $9,055,000 | +854.2% | 555,155 | +646.8% | 3.29% | +1270.0% |
| PTGX | New | PROTAGONIST THERAPEUTICS INC | $8,246,000 | – | 241,119 | +100.0% | 2.99% | – |
| BBIO | Sell | BRIDGEBIO PHARMA INC | $8,241,000 | -73.1% | 494,046 | -24.5% | 2.99% | -61.4% |
| KURA | Buy | KURA ONCOLOGY INC | $7,840,000 | -21.0% | 560,000 | +5.7% | 2.85% | +13.6% |
| TRAVERE THERAPEUTICS INCnote 2.500% 9/1 | $7,731,000 | +9.6% | 7,000,000 | 0.0% | 2.81% | +57.5% | ||
| MRNA | New | MODERNA INCput | $7,619,000 | – | 30,000 | +100.0% | 2.77% | – |
| CERE | Sell | CEREVEL THERAPEUTICS HLDNG I | $7,295,000 | -4.9% | 225,000 | -13.5% | 2.65% | +36.8% |
| NVAX | New | NOVAVAX INCput | $7,154,000 | – | 50,000 | +100.0% | 2.60% | – |
| ARYA SCIENCES ACQUISITN CORP | $6,807,000 | -1.9% | 702,500 | 0.0% | 2.47% | +41.0% | ||
| CYTK | Buy | CYTOKINETICS INC | $6,634,000 | +48.5% | 145,552 | +16.4% | 2.41% | +113.6% |
| ACRS | Buy | ACLARIS THERAPEUTICS INC | $5,816,000 | -7.7% | 400,000 | +14.3% | 2.11% | +32.7% |
| RPTX | New | REPARE THERAPEUTICS INC | $5,732,000 | – | 271,778 | +100.0% | 2.08% | – |
| New | BRIDGEBIO PHARMA INCnote 2.500% 3/1 | $5,529,000 | – | 7,500,000 | +100.0% | 2.01% | – | |
| MDGL | New | MADRIGAL PHARMACEUTICALS INC | $5,508,000 | – | 65,000 | +100.0% | 2.00% | – |
| NAUT | Buy | NAUTILUS BIOTECHNOLOGY INC | $5,438,000 | -9.2% | 1,049,721 | +7.7% | 1.98% | +30.6% |
| ESTA | Buy | ESTABLISHMENT LABS HLDGS INC | $5,238,000 | +22.0% | 77,500 | +29.2% | 1.90% | +75.3% |
| CRIS | New | CURIS INCcall | $4,998,000 | – | 1,050,000 | +100.0% | 1.82% | – |
| CNTA | Buy | CENTESSA PHARMACEUTICALS PLCsponsored ads | $4,720,000 | +39.1% | 419,144 | +106.3% | 1.71% | +100.0% |
| XENE | Buy | XENON PHARMACEUTICALS INC | $4,702,000 | +515.4% | 150,500 | +201.0% | 1.71% | +784.5% |
| BLU | Sell | BELLUS HEALTH INC NEW | $4,025,000 | +23.2% | 500,000 | -6.0% | 1.46% | +77.2% |
| ARYD | Sell | ARYA SCIENCES ACQU CORP IVcl a | $3,972,000 | -34.2% | 400,000 | -33.3% | 1.44% | -5.4% |
| CLDX | Buy | CELLDEX THERAPEUTICS INC NEW | $3,864,000 | +78.2% | 100,000 | +149.0% | 1.40% | +156.0% |
| SNDX | New | SYNDAX PHARMACEUTICALS INC | $3,831,000 | – | 175,000 | +100.0% | 1.39% | – |
| CBAY | New | CYMABAY THERAPEUTICS INC | $3,793,000 | – | 1,122,244 | +100.0% | 1.38% | – |
| RCKT | Buy | ROCKET PHARMACEUTICALS INC | $3,602,000 | +50.2% | 165,000 | +105.7% | 1.31% | +115.8% |
| CRIS | Buy | CURIS INC | $3,094,000 | -31.3% | 650,000 | +13.0% | 1.12% | -1.1% |
| HSAQ | HEALTH SCIENCES ACQ CORP 2 | $3,000,000 | +1.1% | 300,000 | 0.0% | 1.09% | +45.4% | |
| ENVI | ENVIRONMENTAL IMPACT ACQU CO | $2,976,000 | +0.3% | 300,000 | 0.0% | 1.08% | +44.3% | |
| MRTX | Sell | MIRATI THERAPEUTICS INC | $2,934,000 | -39.7% | 20,000 | -27.3% | 1.06% | -13.3% |
| MSAC | MEDICUS SCIENCES ACQUISITION | $2,916,000 | -0.3% | 300,000 | 0.0% | 1.06% | +43.3% | |
| Buy | PROCEPT BIOROBOTICS CORP | $2,501,000 | -16.5% | 100,000 | +27.3% | 0.91% | +19.9% | |
| New | SCIENCE 37 HOLDINGS INC | $1,871,000 | – | 150,000 | +100.0% | 0.68% | – | |
| CVAC | New | CUREVAC N Vcall | $1,716,000 | – | 50,000 | +100.0% | 0.62% | – |
| TVTX | Sell | TRAVERE THERAPEUTICS INC | $1,552,000 | -68.0% | 50,000 | -75.0% | 0.56% | -54.0% |
| CYCC | CYCLACEL PHARMACEUTICALS INC | $1,548,000 | -26.6% | 400,000 | 0.0% | 0.56% | +5.6% | |
| ARKG | New | ARK ETF TRcall | $1,531,000 | – | 25,000 | +100.0% | 0.56% | – |
| NTLA | Sell | INTELLIA THERAPEUTICS INC | $1,182,000 | -41.3% | 10,000 | -33.3% | 0.43% | -15.6% |
| SEER | SEER INCcall | $1,141,000 | -33.9% | 50,000 | 0.0% | 0.41% | -5.0% | |
| INO | New | INOVIO PHARMACEUTICALS INCcall | $998,000 | – | 200,000 | +100.0% | 0.36% | – |
| Buy | RENOVACOR INC | $963,000 | -7.5% | 125,000 | +8.7% | 0.35% | +33.1% | |
| IMTXW | IMMATICS N.V*w exp 07/01/2020 | $834,000 | +4.2% | 190,000 | 0.0% | 0.30% | +50.0% | |
| New | HYPERFINE INC | $552,000 | – | 76,162 | +100.0% | 0.20% | – | |
| RFL | RAFAEL HLDGS INCput | $516,000 | -83.4% | 101,200 | 0.0% | 0.19% | -76.2% | |
| New | LIANBIO SPONSOREDads | $446,000 | – | 72,406 | +100.0% | 0.16% | – | |
| ALDX | Sell | ALDEYRA THERAPEUTICS INC | $403,000 | -76.8% | 100,759 | -49.0% | 0.15% | -66.7% |
| IOVA | Sell | IOVANCE BIOTHERAPEUTICS INC | $382,000 | -89.7% | 20,000 | -86.7% | 0.14% | -85.1% |
| RENOVACOR INC*w exp 99/99/999 | $43,000 | -28.3% | 75,000 | 0.0% | 0.02% | +6.7% | ||
| MSACW | MEDICUS SCIENCES ACQUISITION*w exp 02/12/2026 | $24,000 | 0.0% | 33,333 | 0.0% | 0.01% | +50.0% | |
| CRVS | Exit | CORVUS PHARMACEUTICALS INC | $0 | – | -50,000 | -100.0% | -0.06% | – |
| IMVT | Exit | IMMUNOVANT INCcall | $0 | – | -30,000 | -100.0% | -0.07% | – |
| ASLN | Exit | ASLAN PHARMACEUTICALS LTDads | $0 | – | -250,000 | -100.0% | -0.11% | – |
| KROS | Exit | KEROS THERAPEUTICS INC | $0 | – | -12,500 | -100.0% | -0.12% | – |
| SKINW | Exit | THE BEAUTY HEALTH COMPANY*w exp 05/04/2026 | $0 | – | -34,400 | -100.0% | -0.13% | – |
| CTMX | Exit | CYTOMX THERAPEUTICS INC | $0 | – | -125,000 | -100.0% | -0.16% | – |
| Exit | TANGO THERAPEUTICS INC | $0 | – | -50,000 | -100.0% | -0.16% | – | |
| IPHA | Exit | INNATE PHARMA S Asponsored ads | $0 | – | -125,000 | -100.0% | -0.20% | – |
| ACHL | Exit | ACHILLES THERAPEUTICS PLCsponsored ads | $0 | – | -100,000 | -100.0% | -0.20% | – |
| LUNG | Exit | PULMONX CORP | $0 | – | -25,000 | -100.0% | -0.23% | – |
| BHVN | Exit | BIOHAVEN PHARMACTL HLDG CO L | $0 | – | -7,500 | -100.0% | -0.26% | – |
| GLPG | Exit | GALAPAGOS NVspon adr | $0 | – | -20,000 | -100.0% | -0.27% | – |
| FOLD | Exit | AMICUS THERAPEUTICS INC | $0 | – | -111,400 | -100.0% | -0.27% | – |
| BLI | Exit | BERKELEY LTS INC | $0 | – | -55,000 | -100.0% | -0.27% | – |
| ZYME | Exit | ZYMEWORKS INC | $0 | – | -38,814 | -100.0% | -0.28% | – |
| PCVX | Exit | VAXCYTE INC | $0 | – | -50,000 | -100.0% | -0.32% | – |
| SDGR | Exit | SCHRODINGER INC | $0 | – | -25,000 | -100.0% | -0.34% | – |
| LSAQ | Exit | LIFESCI ACQUISITION II CORP | $0 | – | -150,000 | -100.0% | -0.37% | – |
| BFLY | Exit | BUTTERFLY NETWORK INC | $0 | – | -150,000 | -100.0% | -0.40% | – |
| MREO | Exit | MEREO BIOPHARMA GROUP PLCads | $0 | – | -650,000 | -100.0% | -0.40% | – |
| HZNP | Exit | HORIZON THERAPEUTICS PUB L | $0 | – | -15,000 | -100.0% | -0.42% | – |
| AFIB | Exit | ACUTUS MED INC | $0 | – | -200,000 | -100.0% | -0.45% | – |
| UTHR | Exit | UNITED THERAPEUTICS CORP DEL | $0 | – | -10,000 | -100.0% | -0.47% | – |
| GBT | Exit | GLOBAL BLOOD THERAPEUTICS IN | $0 | – | -75,000 | -100.0% | -0.48% | – |
| HARP | Exit | HARPOON THERAPEUTICS INC | $0 | – | -250,000 | -100.0% | -0.50% | – |
| Exit | GOSSAMER BIO INCnote 5.000% 6/0 | $0 | – | -2,000,000 | -100.0% | -0.53% | – | |
| Exit | TRILLIUM THERAPEUTICS INC | $0 | – | -200,000 | -100.0% | -0.89% | – | |
| NSTG | Exit | NANOSTRING TECHNOLOGIES INC | $0 | – | -75,000 | -100.0% | -0.91% | – |
| EDIT | Exit | EDITAS MEDICINE INCput | $0 | – | -100,000 | -100.0% | -1.04% | – |
| ASND | Exit | ASCENDIS PHARMA A/Ssponsored adr | $0 | – | -35,910 | -100.0% | -1.45% | – |
| XLRN | Exit | ACCELERON PHARMA INC | $0 | – | -35,350 | -100.0% | -1.54% | – |
| OCUL | Exit | OCULAR THERAPEUTIX INC | $0 | – | -750,000 | -100.0% | -1.89% | – |
| SPY | Exit | SPDR S&P 500 ETF TRput | $0 | – | -100,000 | -100.0% | -10.84% | – |
| XBI | Exit | SPDR SER TRput | $0 | – | -700,000 | -100.0% | -22.22% | – |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2022-02-11
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| MORPHIC HOLDING INC | 12 | Q3 2023 | 6.9% |
| KURA ONCOLOGY INC | 12 | Q3 2023 | 7.2% |
| CELLDEX THERAPEUTICS INC NEW | 12 | Q3 2023 | 1.9% |
| IMMATICS N.V | 12 | Q3 2023 | 0.4% |
| CHINOOK THERAPEUTICS INC | 11 | Q2 2023 | 8.4% |
| ESTABLISHMENT LABS HLDGS INC | 11 | Q3 2023 | 8.3% |
| VINCERX PHARMA INC | 11 | Q2 2023 | 4.5% |
| ASCENDIS PHARMA A/S | 11 | Q3 2023 | 4.9% |
| CYTOKINETICS INC | 11 | Q3 2023 | 2.6% |
| INARI MED INC | 10 | Q1 2023 | 6.4% |
View Affinity Asset Advisors, LLC's complete holdings history.
Latest significant ownerships (13-D/G)
| Filed | Shares | Percentage | |
|---|---|---|---|
| Aeglea BioTherapeutics, Inc. | July 03, 2023 | 7,477,000 | 9.2% |
View Affinity Asset Advisors, LLC's complete significant-ownership history.
Latest filings
| Type | Filed |
|---|---|
| 13F-HR | 2024-02-13 |
| SC 13G/A | 2024-02-13 |
| SC 13G/A | 2024-02-13 |
| SC 13G/A | 2024-02-13 |
| 13F-HR | 2023-11-14 |
| 13F-HR/A | 2023-08-21 |
| 13F-HR | 2023-08-14 |
| SC 13G | 2023-07-03 |
| 13F-HR | 2023-05-15 |
| SC 13G/A | 2023-02-13 |
View Affinity Asset Advisors, LLC's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.